Sale!

DCLRE1C Gene Severe Combined Immunodeficiency Athabascan Type Genetic Test

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The DCLRE1C gene severe combined immunodeficiency Athabascan type genetic test is a specialized diagnostic assessment designed to identify mutations in the DCLRE1C gene, which are associated with a specific form of severe combined immunodeficiency (SCID), known as the Athabascan type. This rare and severe genetic disorder primarily affects the immune system, rendering individuals highly susceptible to a wide range of infectious diseases. The condition is particularly prevalent among certain indigenous populations, including the Athabascan people, hence the name.

The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in a laboratory setting to detect any genetic abnormalities in the DCLRE1C gene. Identifying mutations in this gene is crucial for the early diagnosis and management of the condition, allowing healthcare providers to initiate appropriate treatments and interventions, such as bone marrow transplants or gene therapy, to improve the patient’s quality of life and survival chances.

Administered at DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates, the test costs 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by experienced professionals, ensuring accurate and reliable test results. Early diagnosis through this genetic test is vital, as it provides critical information for managing the condition effectively, potentially saving lives and preventing severe complications associated with the disorder.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

DCLRE1C Gene Severe combined immunodeficiency Athabascan type Genetic Test

At DNA Labs UAE, we offer the DCLRE1C Gene Severe combined immunodeficiency Athabascan type Genetic Test at a cost of AED 4400.0. This test is designed to diagnose individuals with severe combined immunodeficiency (SCID), Athabascan type, a rare genetic disorder characterized by a severe impairment of the immune system.

Test Components

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Osteology Dermatology Immunology Disorders

Doctor and Test Department

This test is conducted by our experienced Dermatologist and is performed in our Genetics department.

Pre Test Information

Prior to the test, it is important to provide the clinical history of the patient who is going for the DCLRE1C Gene Severe combined immunodeficiency, Athabascan type NGS Genetic DNA Test. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with DCLRE1C Gene Severe combined immunodeficiency, Athabascan type NGS Genetic DNA Test gene DCLRE1C.

Test Details

The DCLRE1C gene is associated with the development of severe combined immunodeficiency (SCID), Athabascan type. SCID is a group of inherited disorders characterized by a severe impairment of the immune system, making individuals highly susceptible to infections.

The DCLRE1C gene provides instructions for producing a protein called DNA cross-link repair 1C. This protein is responsible for repairing DNA damage that occurs during the development of immune cells. However, mutations in the DCLRE1C gene can result in a nonfunctional or partially functional protein, leading to a defective immune system.

NGS (Next-Generation Sequencing) genetic testing is a high-throughput method used to sequence the entire or specific regions of the genome. In the context of DCLRE1C gene-related SCID, NGS genetic testing can be used to identify mutations or variations in the DCLRE1C gene that may be responsible for the disorder.

By analyzing the genetic sequence of the DCLRE1C gene, NGS genetic testing can help diagnose individuals with SCID, Athabascan type. This can assist in providing appropriate medical management, genetic counseling, and potentially targeted therapies for affected individuals.

Test Name DCLRE1C Gene Severe combined immunodeficiency Athabascan type Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Osteology Dermatology Immunology Disorders
Doctor Dermatologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for DCLRE1C Gene Severe combined immunodeficiency, Athabascan type NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with DCLRE1C Gene Severe combined immunodeficiency, Athabascan type NGS Genetic DNA Test gene DCLRE1C
Test Details

The DCLRE1C gene is associated with a rare genetic disorder called severe combined immunodeficiency (SCID), Athabascan type. SCID is a group of inherited disorders characterized by a severe impairment of the immune system, making individuals highly susceptible to infections.

The DCLRE1C gene provides instructions for producing a protein called DNA cross-link repair 1C. This protein is involved in repairing DNA damage that occurs during the development of immune cells. Mutations in the DCLRE1C gene can result in a nonfunctional or partially functional protein, leading to a defective immune system.

NGS (Next-Generation Sequencing) genetic testing is a high-throughput method used to sequence the entire or specific regions of the genome. In the context of DCLRE1C gene-related SCID, NGS genetic testing can be used to identify mutations or variations in the DCLRE1C gene that may be responsible for the disorder.

By analyzing the genetic sequence of the DCLRE1C gene, NGS genetic testing can help diagnose individuals with SCID, Athabascan type. This can assist in providing appropriate medical management, genetic counseling, and potentially targeted therapies for affected individuals.